skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index

Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states

Annals of the rheumatic diseases, 2018-10, Vol.77 (10), p.1539-1540 [Peer Reviewed Journal]

Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;2018 Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted. ;ISSN: 0003-4967 ;EISSN: 1468-2060 ;DOI: 10.1136/annrheumdis-2018-213184 ;PMID: 29453216

Full text available

  • Title:
    Ankylosing Spondylitis Disease Activity Score (ASDAS): 2018 update of the nomenclature for disease activity states
  • Author: Machado, Pedro M ; Landewé, Robert ; van der Heijde, Désirée
  • Subjects: Ankylosing spondylitis ; Endorsements ; Health risk assessment ; Neuromuscular diseases ; Nomenclature ; Patients ; Rheumatology ; Spondylitis ; University colleges
  • Is Part Of: Annals of the rheumatic diseases, 2018-10, Vol.77 (10), p.1539-1540
  • Description: Correspondence to Dr Pedro M Machado, Centre for Rheumatology and MRC Centre for Neuromuscular Diseases, University College London, London WC1B 5EH, UK; p.machado@ucl.ac.uk The Ankylosing Spondylitis Disease Activity Score (ASDAS) is a measure of axial spondyloarthritis (axSpA) disease activity with validated cut-offs endorsed by the Assessment of SpondyloArthritis international Society (ASAS) and Outcome Measures in Rheumatology (OMERACT).1 2 In the 2016 update of the ASAS-European League Against Rheumatism (EULAR) management recommendations for axSpA, it is recommended that biological disease-modifying antirheumatic drugs should be considered in patients with persistently high disease activity despite conventional treatments, and that the preferred measure to define active disease should be the ASDAS (ASDAS of at least 2.1, ie, high disease activity).3 The 2017 update of treat-to-target recommendations in axial and peripheral SpA recommends that the treatment target should be inactive disease/clinical remission and that low/minimal disease activity may be an alternative treatment target. The compelling argument is the fact that the majority of patients in this ASDAS category have indeed mild disease activity, an observation that is in line with the external constructs that were used to derive the ASDAS cut-off of 2.1: patient and physician global assessments <3 using the 90% specificity criterion to determine the optimal cut-off.1 5 Furthermore, recent publications have shown that the majority of patients with ASDAS values in the ‘moderate disease activity’ category consider themselves as being in a patient-acceptable symptom state (PASS), which can be defined as the maximum level of symptoms with which patients consider themselves to be well. [...]the nomenclature of ASDAS disease activity states was updated by ASAS.
  • Publisher: England: BMJ Publishing Group LTD
  • Language: English
  • Identifier: ISSN: 0003-4967
    EISSN: 1468-2060
    DOI: 10.1136/annrheumdis-2018-213184
    PMID: 29453216
  • Source: ProQuest Central
Back to results list
INSPIRE LIBRARY - TON DUC THANG UNIVERSITY (84-028) 37 755 057 Feedback
19 Nguyen Huu Tho St. Dist.7, HCM thuvien@tdtu.edu.vn

Copyright © 2017 INSPIRE LIBRARY - TON DUC THANG UNIVERSITY

Searching Remote Databases, Please Wait